In June 2017, the FDA approved the combination of dabrafenib and trametinib for metastatic NSCLC patients harboring BRAF V600E mutations based upon the international, multicenter, three-cohort, non-randomized, open-label BRF113928 trial [103,104,105]. This evidence concerns the gene BRAF and non-small cell lung carcinoma.